ANALYSIS OF ADVERSE DRUG REACTION REPORT FORMS ON THE MEDICINES, USED FOR AIDS TREATMENT (REGISTERED IN THE REPUBLIC OF CRIMEA IN THE PERIOD FROM 2011 TO 2016)

According to the data of the World Health Organization (WHO), human immunodeficiency virus (HIV) remains a major global public health problem.

The main method of treating HIV is using highly active antiretroviral therapy (HAART), which is the use of multiple medicines acting on different viral targets. The timely onset of HAART can suppress the replication of the virus in the human body and helps to strengthen its immune system and restore its ability to fight infections. At the same time, the choice of medicines to improve the quality of life and patients’ compliance during antiretroviral therapy should be based on their effectiveness and safety. The aim of this research was to analyze and study the adverse reactions that occur in patients with HIV living in the territory of the Republic of Crimea, when using HAART.

Materials and methods. The objects of research were 274 report cards about the adverse reactions, registered in the regional base (registry) of spontaneous messages called ARCADe (Adverse Reactions in Crimea, Autonomic Database) for the period from 2011 to 2016.

Results. The results of the study showed that the most often adverse reactions were observed when using medicines of the group of Nucleoside Reverse Transcriptase Inhibitors (NRTI). This is explained by the inclusion of NRTI medicines as the main medicine in the method of HAART. Efavirenz (EFV) and Nevirapine (NVP) were absolute leaders among these groups of antiretroviral medicines. Among the combined antiviral medicines active against HIV, the most frequently adverse reactions were associated with the use of a combination of Lamivudine (3TC) and Zidovudine (ZDV). The main clinical manifestations of adverse reactions in the use of combination medicines for treating HIV were a decrease in the level of hemoglobin and the development of anemia. At the same time, in 85% of cases, the patients needed medication in order to correct the resulting adverse drug reaction (ADR). The combination of antiretroviral therapy has often been associated with the development of serious ADR. In case of monotherapy, the main clinical manifestations of adverse reactions were disorders of the central nervous system (dizziness, hallucinations, sleep disorders) and allergic reactions of varying severity (including 1 case of angioedema to “Eferven” (Efavirenz (EFV)),600 mg). Hereby, in almost half of the cases, the usage of antiretroviral medicines of the NRTI group and protease inhibitors caused the development of serious side effects. This confirms the necessity to study and analyze adverse reactions in order to increase the safety of patients’ pharmacotherapy and improve their quality of life.

Conclusion. The study of adverse reactions to the medicines used for treatment of HIV is of a paramount importance in improving the safety and compliance of HIV patients to lifelong pharmacotherapy.

1. Burbello AT. Neblagopriyatnyye pobochnyye reaktsii lekarstvennykh sredstv: posobiye dlya vrachey [Adverse reactions of drugs: a manual for doctors]. 2009. 34 р. Russian.

2. Matveyev AV., Krasheninnikov AE., Egorova EA. Rol «off-label» naznacheniy kak faktora vozniknoveniya nezhelatelnykh pobochnykh reaktsiy na lekarstvennyye sredstva v pediatricheskoy praktike. [The role of “off-label” prescriptions as a factor in the occurrence of unwanted adverse reactions to drugs in pediatric practice.]. Clinical Practice in Pediatrics, 2018;13(4):18–24. DOI: 10.20953/1817-7646-2018-4-18-24.

3. Tsvetov VM. Monitoring neblagopriyatnykh pobochnykh reaktsiy lekarstvennykh preparatov v ambulatorno-poliklinicheskom uchrezhdenii na sovremennom etape. [Monitoring of adverse drug reactions in an outpatient clinic at the present stage]. Theses. Chelyabinsk; 2007: 26. Russian

4. VICh/SPID. Informatsionnyy byulleten [HIV / AIDS. News bulletin]. November 2016. Available at: http://www.who.int/mediacentre/factsheets/fs360/ru. Russian.

5. Shaldina MV. Pirogova IA. Antiretrovirusnaya terapiya kak osnovnoy metod lecheniya VICh-infektsii [Antiretroviral therapy as the main treatment for HIV infection]. Bulletin of the Council of Young Scientists and Specialists of the Chelyabinsk Region. 2017;4(19):71–74. Russian.

6. Spravka VICh-infektsii v RF na 31 dekabrya 2015 goda. Federalnyy nauchno-metodicheskiy tsentr po profilaktike i borbe sos SPIDom FBUN Tsentralnogo NII epidemiologii Rospotrebnadzora [Certificate of HIV infection in the Russian Federation on December 31, 2015. Federal Scientific and Methodological Center for the Prevention and Control of AIDS of the Central Research Institute for Epidemiology of Rospotrebnadzor]. Available at: http://childhiv.ru/wp-content/uploads/2015/04/sprav.pdf. Russian.

7. Bobkova MR. Ingibitory proteazy VICh-1: osobennosti kletochnogo metabolizma i lekarstvennaya ustoychivost. [HIV-1 protease inhibitors: cell metabolism and drug resistance (review]. Therapeutic archive. 2008;80(10): 77–80. Russian.

8. Cohen MS., Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole SV, Mehendale S et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. DOI: 10.1056/NEJMoa1105243.

9. TEMPRANO ANRS 12136 Study Group, Danel C., Moh R, Gabillard D, Badje A, Le Carrou J at al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. DOI: 10.1056/NEJMoa1507198.

10. Gudilina NA, Rostova NB. Nezhelatelnyye pobochnyye reaktsii lekarstvennykh preparatov kak kriteriy bezopasnosti terapii. [Unfavourbale adverse reactions of medicines as the criterion of therapy safety]. Medicinskij al’manah. 2017;3:186–92. DOI: http://dx.doi.org/10.21145/2499-9954-2017-3-186-192. Russian.

11. Yurin OG., Efremova OS. Evropeyskiye i Amerikanskiye rekomendatsii po lecheniyu VICh-infektsii [The European and American guidelines for treatment of HIV infection]. Meditsinskiy Sovet. 2017;4:67–72. Russian.

12. Spravochnik lekarstvennykh preparatov Vidal. [Vidal’s Handbook of medicines]. Available at: https://www.vidal.ru/. Russian.

13. Federalnyy zakon «Ob obrashchenii lekarstvennykh sredstv» 12.04.2010 y. [Federal Law No61 of April 12, 2010 on the Circulation of Medicines]. Available at: http://www.consultant.ru/document/cons_doc_LAW_99350/. Russian.

14. Stepanova EV, Zakharova NG, Toropov SE, Minin PV. Pobochnyye effekty i optimizatsiya vysokoaktivnoy antiretrovirusnoy terapii po materialam Sankt-Peterburgskogo tsentra SPID. VICh-infektsiya i immunosupressiya [Side effects and optimization of highly active antiretroviral therapy according to the materials of the St. Petersburg AIDS Center]. HIV Infection and Immunosuppressive Disorders. 2010;2(3):101–8. Russian.

15. Gromyko NL, Teslova OA, Baranovskaya EI. Antiretrovirusnye preparaty v profilaktike vertikalnoj peredachi VICH [Antiretroviral drugs in preventing vertical HIV transmission]. Recipe. 2008;3(59):132–7. Russian.

16. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170(2):229–38.